
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

WEREWOLF THERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

95075A107

(CUSIP Number)

Ansbert Gadicke
c/o MPM BioImpact LLC, 339 Boylston Street, Suite 1100
Boston, MA, 02116
617-425-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/14/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 95075A107

Name of reporting person

1

MPM BioVentures 2014, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE
Sole Voting Power

7 1,461,054.00
Number of Shares Beneficially Owned by Each Reporting Person With:
8 Shared Voting Power
0.00
9 Sole Dispositive Power
1,461,054.00
10 Shared Dispositive Power
0.00
Aggregate amount beneficially owned by each reporting person

11 1,461,054.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 3.0 %
Type of Reporting Person (See Instructions)

14 PN

SCHEDULE 13D

CUSIP No. 95075A107

1 Name of reporting person
MPM BioVentures 2014 (B), L.P.
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE
7 Sole Voting Power

Number of

Shares	
Beneficially	97,450.00
Owned by	Shared Voting Power
Each	8
Reporting	0.00
Person	Sole Dispositive Power
With:	9
	97,450.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	97,450.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	0.2 %
	Type of Reporting Person (See Instructions)
14	PN

SCHEDULE 13D

CUSIP No. 95075A107

1	Name of reporting person
	MPM Asset Management Investors BV2014 LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	50,289.00
Number of	Shared Voting Power
Shares	8
Beneficially	0.00
Owned by	Sole Dispositive Power
Each	9
Reporting	50,289.00
Person	Shared Dispositive Power
With:	10
	0.00
11	Aggregate amount beneficially owned by each reporting person

50,289.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.1 %

Type of Reporting Person (See Instructions)

14

OO

SCHEDULE 13D

CUSIP No. 95075A107

Name of reporting person

1

UBS Oncology Impact Fund L.P.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

1,208,810.00

Number of
Shares

Shared Voting Power

Beneficially 8

0.00

Owned by

Sole Dispositive Power

Each

Reporting 9

1,208,810.00

Person

With:

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

1,208,810.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

2.5 %

Type of Reporting Person (See Instructions)

14

PN

SCHEDULE 13D

CUSIP No. 95075A107

1 Name of reporting person
MPM BioVentures 2014 GP LLC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power
0.00

Number of Shares Beneficially Owned by Each Reporting Person With: 8 Shared Voting Power
1,558,504.00

9 Sole Dispositive Power
0.00

10 Shared Dispositive Power
1,558,504.00

11 Aggregate amount beneficially owned by each reporting person
1,558,504.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)
3.2 %

14 Type of Reporting Person (See Instructions)
OO

SCHEDULE 13D

CUSIP No. 95075A107

1 Name of reporting person
MPM BioVentures 2014 LLC
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 DELAWARE

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 0.00
Shared Voting Power

9 1,608,793.00
Sole Dispositive Power

10 0.00
Shared Dispositive Power

11 1,608,793.00
Aggregate amount beneficially owned by each reporting person

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
Percent of class represented by amount in Row (11)

14 3.3 %
Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 95075A107

1 Name of reporting person
Oncology Impact Fund (Cayman) Management L.P.
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With: 7 Sole Voting Power

8 0.00

Owned by Each Reporting Person With:	8	Shared Voting Power
		1,208,810.00
		Sole Dispositive Power
	9	0.00
		Shared Dispositive Power
	10	1,208,810.00
11		Aggregate amount beneficially owned by each reporting person
		1,208,810.00
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
		<input type="checkbox"/>
13		Percent of class represented by amount in Row (11)
		2.5 %
14		Type of Reporting Person (See Instructions)
		PN

SCHEDULE 13D

CUSIP No. 95075A107

1	Name of reporting person
	MPM BioImpact LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions)
	WC
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	<input type="checkbox"/>
6	Citizenship or place of organization
	DELAWARE
	Sole Voting Power
	7
	0.00
	Shared Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With:	8
	1,208,810.00
	Sole Dispositive Power
	9
	0.00
	Shared Dispositive Power
	10
	1,208,810.00
11	Aggregate amount beneficially owned by each reporting person
	1,208,810.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Percent of class represented by amount in Row (11)
13 2.5 %
14 Type of Reporting Person (See Instructions)
OO

SCHEDULE 13D

CUSIP No. 95075A107

1 Name of reporting person
ANSBERT GADICKE
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 UNITED STATES

7 Sole Voting Power
0.00
Number of Shares Beneficially Owned by Each Reporting Person With:
8 Shared Voting Power
3,368,670.00
9 Sole Dispositive Power
0.00
10 Shared Dispositive Power
3,368,670.00
Aggregate amount beneficially owned by each reporting person

11 3,368,670.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 6.9 %
Type of Reporting Person (See Instructions)

14 IN

SCHEDULE 13D

1 Name of reporting person
LUKE EVNIN
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 UNITED STATES
Sole Voting Power

7 0.00
Number of Shares Beneficially Owned by Each Reporting Person With:
Shared Voting Power

8 2,159,860.00
Sole Dispositive Power

9 0.00
Shared Dispositive Power

10 2,159,860.00
Aggregate amount beneficially owned by each reporting person

11 2,159,860.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 4.4 %
Type of Reporting Person (See Instructions)

14 IN

SCHEDULE 13D

1 Name of reporting person
Todd Foley
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

UNITED STATES

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially

8

Owned by

1,608,793.00

Each

Sole Dispositive Power

Reporting

9

Person

0.00

With:

Shared Dispositive Power

10

1,608,793.00

Aggregate amount beneficially owned by each reporting person

11

1,608,793.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

3.3 %

Type of Reporting Person (See Instructions)

14

IN

SCHEDULE 13D

CUSIP No. 95075A107

Name of reporting person

1

MPM ASSET MANAGEMENT LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

Number of
Shares

231,408.00

Beneficially

8

Owned by

Shared Voting Power

Each

Reporting Person	0.00
With:	Sole Dispositive Power
	9
	231,408.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	231,408.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	0.5 %
	Type of Reporting Person (See Instructions)
14	OO

SCHEDULE 13D

CUSIP No. 95075A107

1	Name of reporting person
	MPM ONCOLOGY INNOVATIONS FUND LP
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	<input type="checkbox"/>
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
	7
	319,659.00
Number of Shares Beneficially Owned by Each Reporting Person	8
With:	Shared Voting Power
	0.00
	Sole Dispositive Power
	9
	319,659.00
	Shared Dispositive Power
	10
	0.00
	Aggregate amount beneficially owned by each reporting person
11	319,659.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>

13 Percent of class represented by amount in Row (11)

0.7 %

Type of Reporting Person (See Instructions)

14

PN

SCHEDULE 13D

CUSIP No. 95075A107

Name of reporting person

1

MPM Oncology Innovations Fund GP LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

Owned by

319,659.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

319,659.00

Aggregate amount beneficially owned by each reporting person

11

319,659.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.7 %

Type of Reporting Person (See Instructions)

14

OO

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock

Name of Issuer:

(b) WEREWOLF THERAPEUTICS, INC.

Address of Issuer's Principal Executive Offices:

(c) 200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN, MASSACHUSETTS , 02472.

Item 1 Explanatory Note: This Amendment No. 5 to Schedule 13D ("Amendment No. 5") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of Werewolf Therapeutics Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the "SEC") on May 14, 2021 and as amended by Amendment No. 1 filed November 4, 2025, Amendment No. 2 filed November 17, 2025, Amendment No. 3 filed December 3, 2025 and Amendment No. 4 filed December 29, 2025 (as amended, the "Original Schedule 13D"). This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Stock by certain Filing Persons. Items 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment No. 5 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

Item 5. Interest in Securities of the Issuer

See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 5 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person. The Common Stock is held as follows: * 1,461,054 shares are held directly by BV 2014; * 97,450 shares are held directly by BV 2014(B); * 50,289 shares are held directly by AM BV2014 LLC; * 319,659 shares are held directly by MPM OIF; * 231,408 shares by AM LLC; and * 1,208,810 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. MPM OIF GP is the general Partner of MPM OIF and, accordingly, may be deemed to beneficially own the shares held by MPM OIF. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadick and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Drs. Gadick and Evnin are the members of AM LLC and managers of MPM OIF GP and, accordingly, may be deemed to beneficially own the shares held by AM LLC and MPM OIF. Dr. Gadick is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 48,540,200 Common Stock outstanding as of October 29, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2025.

(a) See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 5 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.

(b) The Reporting Persons sold the following Common Stock in the open market since the date of filing Amendment No. 4: Date of Price Range Ave. Price Sold by Sold by Sold By Sold by Sold by Sold by Sale BV 2014 BV AM BV2014 MPM OIF AM LLC UBS 2014(B) LLC Oncology 12/30/25 \$0.6085-\$0.63 \$0.61 23,551 1,571 811 5,186 3,728 19,449 12/31/25 \$0.6038-\$0.6359 \$0.62 16,870 1,125 582 3,715 2,670 13,932 01/02/26 \$0.62-\$0.6499 \$0.63 12,549 837 432 2,764 1,986 10,363 01/05/26 \$0.63435-\$0.6549 \$0.64 12,420 828 429 2,735 1,966 10,257 01/06/26 \$0.64-\$0.6599 \$0.65 27,548 1,837 948 6,067 4,361 22,751 01/07/26 \$0.6276-\$0.6598 \$0.64 8,053 537 277 1,773 1,275 6,651 01/08/26 \$0.6243-\$0.6368 \$0.63 5,215 348 180 1,148 825 4,307 01/09/26 \$0.6019-\$0.6583 \$0.61 16,678 1,112 575 3,673 2,640 13,773 01/12/26 \$0.5608-\$0.606 \$0.57 39,861 2,659 1,373 8,778 6,309 32,919 01/13/26 \$0.53675-\$0.5697 \$0.55 29,195 1,947 1,006 6,429 4,621 24,110 01/14/26 \$0.5524-\$0.5857 \$0.57 20,692 1,380 712 4,557 3,275 17,088 01/15/26 \$0.5305-\$0.59 \$0.55 25,285 1,686 872 5,568 4,002 20,881 01/16/26 \$0.535-\$0.5495 \$0.54 26,213 1,749 893 5,775 4,152 21,647

(c) Inapplicable.

(d) Inapplicable.

(e) Inapplicable.

Item 7. Material to be Filed as Exhibits.
Exhibit 99.C - Joint Filing Statement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MPM BioVentures 2014, L.P.

Signature: /s/ Ansbert Gadick

Name/Title: Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P.

Date: 01/16/2026

MPM BioVentures 2014 (B), L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P.

Date: 01/16/2026

MPM Asset Management Investors BV2014 LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC

Date: 01/16/2026

UBS Oncology Impact Fund L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.

Date: 01/16/2026

MPM BioVentures 2014 GP LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC

Date: 01/16/2026

MPM BioVentures 2014 LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Director

Date: 01/16/2026

Oncology Impact Fund (Cayman) Management L.P.

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P.

Date: 01/16/2026

MPM BioImpact LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Managing Partner

Date: 01/16/2026

ANSBERT GADICKE

Signature: /s/ Ansbert Gadicke

Name/Title: Ansbert Gadicke

Date: 01/16/2026

LUKE EVNIN

Signature: /s/ Luke Evnin

Name/Title: Luke Evnin

Date: 01/16/2026

Todd Foley

Signature: /s/ Todd Foley

Name/Title: Todd Foley

Date: 01/16/2026

MPM ASSET MANAGEMENT LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Member

Date: 01/16/2026

MPM ONCOLOGY INNOVATIONS FUND LP

Signature: /s/ Ansbert Gadicke

Manager of MPM Oncology Innovations Fund GP

Name/Title: LLC, the General Partner of MPM Oncology
Innovations Fund, L.P.

Date: 01/16/2026

MPM Oncology Innovations Fund GP LLC

Signature: /s/ Ansbert Gadicke

Name/Title: Manager

Date: 01/16/2026

Joint Filing Statement

I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Werewolf Therapeutics, Inc. is filed on behalf of each of the undersigned.

Date: January 16, 2026

MPM BioVentures 2014, L.P.

By: MPM BioVentures 2014 GP LLC,
its General Partner

By: MPM BioVentures 2014 LLC,
Its Managing Member

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Director

MPM BioVentures 2014 (B), L.P.

By: MPM BioVentures 2014 GP LLC,
its General Partner

By: MPM BioVentures 2014 LLC,
Its Managing Member

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Director

MPM Asset Management Investors BV 2014 LLC

By: MPM BioVentures 2014 LLC
Its: Manager

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Director

MPM BioVentures 2014 GP, LLC

By: MPM BioVentures 2014 LLC,
Its Managing Member

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Director

MPM BioVentures 2014 LLC

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Director

MPM Asset Management LLC

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Member

MPM Oncology Innovations Fund LP

By: MPM Oncology Innovations Fund GP LLC
its General Partner

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Manager

MPM Oncology Innovations Fund GP LLC

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Manager

UBS Oncology Impact Fund, L.P.

By: Oncology Impact Fund (Cayman) Management L.P.,
its General Partner
By: MPM BioImpact LLC,
Its General Partner

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Partner

Oncology Impact Fund (Cayman) Management L.P.

By: MPM BioImpact LLC,
Its General Partner

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Partner

MPM BioImpact LLC

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke
Title: Managing Partner

By: /s/ Todd Foley
Name: Todd Foley

By: /s/ Luke Evnin
Name: Luke Evnin

By: /s/ Ansbert Gadicke
Name: Ansbert Gadicke